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Abstract
Background: Thirty-nine patients have been described with deletions involving chromosome
6p25. However, relatively few of these deletions have had molecular characterization. Common
phenotypes of 6p25 deletion syndrome patients include hydrocephalus, hearing loss, and ocular,
craniofacial, skeletal, cardiac, and renal malformations. Molecular characterization of deletions can
identify genes that are responsible for these phenotypes.
Methods: We report the clinical phenotype of seven patients with terminal deletions of
chromosome 6p25 and compare them to previously reported patients. Molecular characterization
of the deletions was performed using polymorphic marker analysis to determine the extents of the
deletions in these seven 6p25 deletion syndrome patients.
Results: Our results, and previous data, show that ocular dysgenesis and hearing impairment are
the two most highly penetrant phenotypes of the 6p25 deletion syndrome. While deletion of the
forkhead box C1 gene (FOXC1) probably underlies the ocular dysgenesis, no gene in this region is
known to be involved in hearing impairment.
Conclusions: Ocular dysgenesis and hearing impairment are the two most common phenotypes
of 6p25 deletion syndrome. We conclude that a locus for dominant hearing loss is present at 6p25
and that this locus is restricted to a region distal to D6S1617. Molecular characterization of more
6p25 deletion patients will aid in refinement of this locus and the identification of a gene involved
in dominant hearing loss.
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Delineation of deletion syndromes is important to
human health and patient care. Careful description of
deletion syndromes allows improved diagnosis and more
accurate prognosis for patients suspected to have chromo-
somal deletions. In addition to improving patient care, we
can also glean more about the biology of the genes
involved in the deletions. Characteristic phenotypes of
patients with 6p25 deletion syndrome are hydrocephalus,
hearing impairment, and ocular, craniofacial, skeletal,
cardiac, and renal malformations [1]. Excluding ring chro-
mosomes or products of unbalanced translocations, thirty
nine patients have been reported with terminal [1-19] or
interstitial [4,18,20-22] 6p25 deletions. Unfortunately,
relatively few of these patients have had the deletions
characterized at a molecular level. We present detailed
clinical reports and molecular characterizations of three
patients with terminal deletions of chromosome 6p that
were briefly reported previously (Z.K., C.C., and
GMO6222 from [9]), and four patients with terminal
deletions of chromosome 6p as a result of unbalanced
translocations (E.S. from [23] and three unreported
cases). By comparing our patients to patients with molec-
ularly characterized terminal deletions in the literature,
we determined that ocular malformations and hearing
loss are the two most highly penetrant phenotypes. While
ocular malformations are likely due to deletions of the
FOXC1 gene, the cause of the hearing impairment is
unknown. Based on our results, we are able to define the
minimal critical interval containing a locus for dominant
hearing impairment as a 4 megabase (Mb) region distal to
D6S1617.
Methods
Microsatellite analysis
Patient 1 DNA was isolated from a cell line supplied from
Coriell Institute For Medical Research Cell Repository
(#GMO6222). For all other patients, DNA was extracted
from peripheral blood leukocytes [24] collected in EDTA
tubes after informed written consent was obtained. To
determine the number of alleles for polymorphic loci, 35S-
dATP was directly incorporated into PCR products. The
PCR products were then separated on 6% polyacrylamide
gels. Patients were considered to be heterozygous for a
locus when two alleles were observed, and homozygous/
hemizygous for a locus when only one allele was
observed. To maximize the chances of detecting heterozy-
gosity for a particular marker, markers with heterozygosity
in excess of 75% were chosen with the exception of
D6S942 and D6S1006, which have heterozygosity of
approximately 50% and 61% respectively. Marker infor-
mation can be obtained from http://
www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?db=unists.
Clinical reports
Clinical reports for each patient were obtained from the
physician who referred the patient. To be thorough, in
addition to reporting phenotypes observed, we also
reported when a specific phenotype was looked for but
not observed. The number of patients in the literature
with the same clinical phenotypes are indicated in Table
1. Table 2 is a summary of the patients for whom molec-
ular characterizations of the deletion have been
determined.
Patient 1 – 46, XX, del(6)(p24)
Patient 1 sample and clinical details were obtained from
Coriell Institute For Medical Research Cell Repository
(#GMO6222). The patient had Dandy-Walker cyst,
hydrocephalus, Peters' anomaly, hypertelorism, ear tags,
low set ears, and normal Hageman factor level in blood.
Patient 2 – 46, XY, del(6)(p24)
Patient 2 had bilateral microphthalmia, corneal opacities,
interstitial keratitis and nystagmus. Craniofacial malfor-
mations included microcephaly, hypertelorism, low set,
posteriorly angulated ears, and a high arched palate. The
patient had severe, progressive, congenital scoliosis and
profound bilateral clubfoot. An examination of the chest
revealed widely spaced nipples. An x-ray was conducted
but was unremarkable. Cardiac findings included a grade
II to grade III murmur, a patent ductus arteriosus (PDA),
a patent foramen ovale (PFO), right ventricular hypertro-
phy and left axis deviation. There was no ventricular septal
defect (VSD) and the PFO closed with time. Hydrocepha-
lus was noted at birth and a brain MRI revealed Dandy-
Walker variant. The corpus callosum was thin and
upwardly bowed and the middle and inferior portions of
the cerebellar vermis were absent. The patient had severe
hearing impairment. Genitourinary malformations
included micropenis and hydronephrosis secondary to
left ureteropelvic junction obstruction. The patient has a
history of chronic oliguria, and chronic neutropenia.
Results of liver and renal function tests were normal.
Patient 3 – 46, XY, del(6)(p24)
Patient 3 had slanted palpebral fissures, shallow orbits,
bilateral hyperopia, Rieger malformation, hypoplastic
irides, mild megalocornea, sclerocornea, and bilateral
crescentic hyperpigmentation of the retina. The lenses
were clear and the intraocular pressures (IOP) were nor-
mal. There was no nystagmus or strabismus and the optic
nerve head, macula and vessels appeared normal. Cranio-
facial malformations included hypertelorism, brachyc-
ephaly, flat mid-face, low-set ears, small nose, broad nasal
bridge, frontal bossing, and mild micrognathia. The
patient also had a short neck, scoliosis, proximately flexed
thumbs, club feet, and mild clinodactyly of the 5th fingers.
His nipples were widely spaced and there were fivePage 2 of 9
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PATIENT 1 2 3 4 5 6 7 # Lit. References
PHENOTYPE
Craniofacial
Hypertelorism + + + - + + + 14 [1-4, 6, 10, 12, 14, 16, 19, 25, 28, 45]
Low/rotated ears + + + - + + + 24 [1-4, 6-8, 10-17, 19-22, 25, 28, 45]
Nasal bridge + - + + 14 [1, 2, 6, 7, 12, 13, 17, 19, 22, 25, 46]
Arched/cleft palate + - + 15 [2, 3, 6, 8, 10-12, 15-17, 20, 25, 28]
Micrognathia + - + + 11 [4, 6, 11, 12, 14, 17, 20, 25]
Short neck + - + + 13 [1, 2, 6, 10-12, 15, 17, 20]
Ocular
Anterior Segment + + + + + + + 17 [1-4, 6, 10, 14, 16, 18, 19, 21, 28, 45]
Microphthalmia + - - + 3 [4, 8, 15]
Nystagmus + - + 3 [4, 15, 22]
Skeletal
Chest - - + - 8 [1, 4, 8, 11, 12, 22]
Spine + + - + + + 3 [8, 28, 46]
Hands + - + + 22 [1, 2, 4, 6-8, 10, 12, 13, 17, 19-22, 25, 45, 46]
Feet + + - + 17 [1, 2, 4, 8, 10, 12, 15, 17, 19, 20, 22, 25, 45, 46]
Joints - + 6 [6, 8, 17, 22, 25, 46]
Cardiac
VSD - + - - - 6 [4, 12, 13, 15, 16, 22]
PDA + - + - - 9 [12-14, 16, 20-22, 45]
PFO + + - + - -
ASD - + - - 6 [3, 4, 12, 19, 45]
Other + + 10 [1, 2, 4, 8, 10-12, 22, 25, 28]
Hydrocephaly + + + - + - - 11 [2, 3, 6, 8, 12, 14, 17, 18, 20, 25, 45]
Renal + - + 6 [1, 8, 12, 15, 20, 21]
Hearing Impairment + + + - 9 [1, 10, 17-19, 25, 45, 46]
Nipples + + - + 10 [1, 2, 6, 12, 17, 21, 46]
Genitalia + - - - 12 [1, 2, 7, 10-12, 16, 21, 22, 45, 46]
Finger/toenails + - + 8 [1, 3, 7, 12, 15, 20, 25]
Eczema + - 1 [10]
'# Lit' is the number of patients with the phenotype of the 39 patients described in the literature. Blank fields indicate the phenotype was not 
specifically documented as present or absent
Table 2: Clinical features of patients with characterized terminal deletions.
Patients with Characterized Terminal Deletions
1 2 3 4 5 6 7 A B C D E F G H I J K L Frequency observed/reported
Phenotypes
Anterior Segment + + + + + + + + + - + + + + + - + + + 17/19 (89%)
Hypertelorism + + + - + + + + + + + - + + 12/14 (86%)
Hearing Impairment + + + + - + + + + + + + + + + 14/15 (93%)
Short Neck + - + + - + - - - 4/9 (44%)
Clinodactyly/ Syndactyly + - + + + - - 4/8 (50%)
Brain Malformation + + + - + - - + + - + - - + 8/14 (57%)
Heart Malformation + + - + - - + + + + - - + + 9/14 (64%)
Renal Malformation + - + + - - - - - - 3/10 (30%)
Patients A-L are defined in Figure 2 legend. Blank fields indicate the phenotype was not specifically documented as present or absent.Page 3 of 9
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tricuspid valve regurgitation; however, all three resolved
by the age of one year without intervention. Dandy
Walker variant, agenesis of the corpus callosum and brain-
stem, seizures and profound bilateral deafness were all
present. His knees were normal and hips were stable in all
ranges of motion but there was delayed ossification of the
femoral and humeral heads. Bone age was consistent with
a one-year-old child when the patient was two years of
age. Fingernails and toenails were soft and the patient had
eczema. Genitalia, liver and spleen were all normal.
Schematic diagram of the distal tip of human chromosome 6pFigure 1
Schematic diagram of the distal tip of human chromosome 6p. The black boxes indicate regions where the patients are not 
deleted. White boxes indicate the minimum extent of the deletion. Grey boxes indicate the maximum extent of the deletion. 
Markers used are listed to the left of the patients chromosomes under locus. Genes in this region are listed in bold print. The 
genetic distance of markers, in Mb (megabases) from the telomere, are also indicated.Page 4 of 9
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Patient 4 had an unbalanced translocation resulting in
monosomy for 6p25-ter and trisomy of 4p14-ter. The
patient had congenital glaucoma, nystagmus, strabismus
and Rieger malformation including posterior embryo-
toxon, iris adhesions, bilateral elevated IOP and a diffuse
corneal opacity on the right eye. This patient had no
craniofacial malformations, cardiac murmur, neurologi-
cal abnormalities, or remarkable abnormalities of the
chest, hands and feet or kidneys.
Patient 5 – 46, XY, der(6)t(6;8)(p25;q24.1)
Patient 5 had an unbalanced translocation resulting in
monosomy for 6p25-ter and trisomy for 8q24.1-ter. At
birth the infant was in the 10th centile for height and
weight, was hypotonic and had little spontaneous move-
ment. He had Reiger anomaly including ectropian uveae
with adhesions around the entire iridocorneal angle and
bilateral congenital glaucoma. The optic nerve head
appeared normal. Facial malformations included turri-
cephaly, hypertelorism and low set, anteriorly displaced
ears. The patient had kyphoscoliosis, hemivertebrae (T5-
T6), and did not have a full complement of ribs. Abdom-
inal ultrasound, shoulders and pelvis were all unremarka-
ble. Nail hypoplasia was observed and the patient had
sparse eyebrows and lashes. Cardiac malformations were
atrial septal defect (ASD), PDA and PFO. He had mild
hydrocephalus and hearing loss, however, the cerebellum
was normal and an EEG was unremarkable.
Patient 6 – 46, XX, der(6)t(2;6)(q32;p24)
Patient 6 had an unbalanced translocation resulting in
monosomy for 6p24-ter and trisomy for 2q32-ter. She
had bilateral aniridia, and a vascularized corneal opacifi-
cation but IOP was normal in each eye. The left eye was
smaller than the right and the right eye had extensive ret-
inal pigment epithelial washout and thinning of the ret-
ina. Craniofacial malformations included
microdolichocephaly, telecanthus, hypertelorism, low-set
ears, a broad nasal bridge, cleft palate, micrognathia, long
philtrum, prominent premaxilla and a short neck. She
had adducted thumbs and camptodactyly of her hands
and a valgus deformity of the left foot. The patient also
had limited flexion and extension of elbows, knees, and
hips and had asymmetrical hypoplasia of vertebrae T12.
As an infant the patient had apneic spells with cyanosis
and bradycardia while feeding although the cardiovascu-
lar system, chest, and abdomen were unremarkable upon
examination. A computed tomography scan of the head
was normal. The patient had progressive hearing loss and
was fitted for a hearing aid at the age of 7 months.
Genitalia were normal but right hydronephrosis and a
bilateral cystouretero reflux were documented.
Patient 7
Patient 7 had an unbalanced translocation resulting in
monosomy of 6p25-ter and a trisomy of the terminal por-
tion of chromosome 10p. She had hypotonia, mild devel-
opmental delay and Rieger anomaly. Craniofacial
malformations included hypertelorism, a flat nasal
bridge, small, low set ears, micrognathia, prognathia and
a small mouth with protruding tongue. The patient had
scoliosis, a short neck, widespread nipples and malforma-
tion of both hands. There was no heart murmur, neuro-
logical malformations or hearing impairment.
Results
In cases where DNA was not available from a transmitting
parent, we could only define the maximum size of the
deletion. A terminal deletion can be no larger than the
boundary defined by the most distal marker that is heter-
ozygous. At markers distal to this, where the patient has a
single allele, the patient may be homozygous or may be
deleted and therefore is hemizygous. By using highly pol-
ymorphic markers we increased the odds that a single
allele, at consecutive markers, indicates a deletion.
No parental DNA was available for Patients 1, 2, 4 or 6.
Patients 1 and 2 were both homozygous for D6S1006 but
heterozygous for D6S277. All markers tested distal to
D6S277 had single alleles and therefore the maximum
deletion sizes for Patients 1 and 2 are 8.4 Mb distal to
D6277 (Figure 1). A DNA sample was provided from the
mother of Patient 3. Microsatellite analysis indicated that
the deletion in Patient 3 was not of maternal origin so
only the maximum deletion size could be determined.
Patient 3 had a single allele for all markers tested except
D6S1006 which was heterozygous. Therefore the maxi-
mum deletion size for Patient 3 is 13.0 Mb distal to
D6S1006 (Figure 1). Patient 4 had a single allele for
D6S942 and was heterozygous for D6S967 thus the max-
imum deletion for this patient is 1.4 Mb distal to D6S967
(Figure 1). We determined Patient 5 to have a deletion of
paternal origin. The patient is deleted for D6S942,
D6S967, and D6S344 but not D6S1617 indicating the
deletion breakpoint is between 1.5 Mb and 4.2 Mb (Figure
1). Patient 6 had single alleles for D6S942, D6S967, and
D6S344 but was heterozygous for D6S1617. Therefore the
maximum deletion for Patient 6 is 4.2 Mb distal to
D6S1617 (Figure 1). We determined Patient 7 to have a
deletion of maternal origin. The patient was deleted for
D6S942, D6S967, D6S344, D6S1617, D6S1713, but not
D6S477 indicating the deletion breakpoint is between 4.3
and 6.1 Mb (Figure 1).
Discussion and conclusions
We have presented clinical and molecular characteriza-
tions of seven patients with 6p25 terminal deletion syn-
drome. Of 39 described cases of terminal deletions ofPage 5 of 9
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with ocular, craniofacial, skeletal, cardiac, and renal mal-
formations, hearing loss, and hydrocephalus (Table 1).
The phenotypic variation between these patients may be
due to a variety of genetic or non-genetic factors (includ-
ing additional chromosomal rearrangements as in
patients 4, 5, 6, and 7). Molecular characterization of the
deletions can allow us to begin to determine the genetic
factors involved. However, only 19 patients (7 reported
here and 12 from the literature) have had deletions char-
acterized at a molecular level (Table 2). By molecular
characterization of the deletions in our new patients and
comparing them to previously described patients we have
determined that ocular dysgenesis and hearing impair-
ment are highly penetrant phenotypes associated with the
6p25 deletion syndrome.
Ocular dysgenesis
Ocular anterior segment dysgenesis, is present in 17 of the
19 patients with molecularly characterized deletions. The
two patients without anterior segment dysgenesis were
from the same report [25], however, both patients had
fundus exams and therefore it is unlikely that anterior seg-
ment dysgenesis would have been overlooked unless it
Schematic of extent of deletions for 12 patients in the literature with deletions characterized at a molecular levelFigure 2
Schematic of extent of deletions for 12 patients in the literature with deletions characterized at a molecular level. The black 
boxes indicate regions where the patients are not deleted. White boxes indicate the minimum extent of the deletion. Grey 
boxes indicate markers that may or may not be deleted. Genes in this region are listed in bold print. The genetic distance of 
markers, in Mb (megabases) from the telomere, are also indicated. The source of the information is as follows: Patient A [19], 
Patient B [28], Patient C is case 2 from [25] and CA from 1, Patients D-G [18], Patient H [10] and SG from [1], Patient I is case 
1 from [25] and BD from [1], Patient J is HH from [1], Patient K is JW from [1], Patient L is case 2 from [5].Page 6 of 9
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tions or duplications, are well established to cause ante-
rior segment dysgenesis [9,18,26-32]. Patients 1, 2, 3, 5, 6,
and 7 have maximum deletions that include FOXC1 and
have ocular malformations consistent with those previ-
ously reported. Interestingly, the maximum deletion for
Patient 4 does not include FOXC1, however, this patient
has an ocular phenotype similar to that associated with
FOXC1 mutations. It is possible that the deletion in this
patient perturbs FOXC1 regulatory elements.
Alternatively, since this patient has an unbalanced trans-
location, the phenotype may be caused by some other
aspect of the chromosomal rearrangement, however,
patients with 4p trisomy do not typically have these types
of ocular malformations [33].
Hearing impairment
The second phenotype observed with a high penetrance is
hearing impairment. Of 15 patients assessed, 14 of them
had hearing impairment (Table 2). This proportion is very
similar to that of patients with ocular dysgenesis and sug-
gests that there may be a dominant locus for hearing
impairment. Since there is phenotypic variability, and
since absence of a reported phenotype may reflect the fail-
ure to assay the phenotype, it is prudent to only use
affected individuals to refine this genetic locus. Two recent
reports suggest that this locus is distal to a marker
D6S1574 (which is between D6S477 and D6S1617) [34]
and distal to GMDS (at 1.6 Mb) [19] respectively. Data
from our study confirms this observation. Patients 5 and
6 both have hearing loss and both exclude marker
D6S1617 from the critical interval. Therefore, we con-
clude that a dominant locus for hearing loss exists distal
to D6S1617. Since FOXC1 is in this critical interval, it is
possible that deletion of FOXC1 underlies the hearing
impairment. Similarly, some patients mapped to 13q14
have anterior segment dysgenesis and hearing defects that
may be caused by a single gene[35].
Variably associating phenotypes
Patients 1, 2, 3, and 5, had hydrocephalus. This is consist-
ent with these patients being deleted for FOXC1. Mice that
are homozygous for a null allele of Foxc1 also have con-
genital hydrocephalus [9,32] and deletion of one copy of
FOXC1 is suggested to cause hydrocephaly in humans [9].
However, not all patients deleted for FOXC1 (here or in
the literature) have hydrocephalus (for example, Patient 8
is deleted for FOXC1 but did not have hydrocephalus)
and thus other factors must contribute to the develop-
ment of this disorder.
FOXC1 is also involved in heart, renal, and skeletal devel-
opment [9,32,36-38] and has been implicated in human
congenital heart disease [28,37,38]. Deletion of FOXC1
may contribute to the cardiac malformations observed in
Patients 1, 2, 3 and 5. Renal examinations were only
reported for three patients in this study. Patients 2 and 6
had hydronephrosis and FOXC1 is within the deletion
interval for these patients. All patients potentially deleted
for FOXC1 in this study have malformations of the spine
or vertebrae and often of the hands and feet.
Bone morphogenetic proteins (BMPs) are involved in a
large number of developmental processes [39] and thus a
deletion may contribute to many aspects of the develop-
mental phenotypes. Patients 1, 2, and 3 have maximum
deletions encompassing BMP6. BMP6 is involved in ossi-
fication of the sternum [40] and thus may be involved in
delayed bone ossification observed in Patient 3.
Patient 3 has the largest maximal deletion in our study.
The maximal deletion includes the genes TFAP2A (Tran-
scription factor AP2 alpha), and ET-1 (Endothelin 1).
Both genes are involved in otic, craniofacial, and cardiac
development [41-44], while TFAP2A is further involved in
renal and skeletal development [41-43]. Thus possible
deletion of these genes in Patient 3 may influence many
aspects of his phenotype including scoliosis, cardiac,
renal, craniofacial, and ocular malformations and hearing
impairment.
We have presented clinical and molecular characteriza-
tion of 7 patients with 6p25 terminal deletion syndrome.
Our data, and data from additional patients in the litera-
ture, define the 6p25 deletion syndrome as having highly
penetrant ocular malformations and hearing impairment.
Additionally, there is variable association with hydro-
cephaly, craniofacial, skeletal, cardiac, and renal malfor-
mations. Based on our data, we suggest that the minimal
critical interval for a dominant locus for hearing impair-
ment be reduced to the interval distal to marker D6S1617.
Employment of other molecular characterization tech-
niques (such as FISH) would provide more informativity
in cases where a transmitting parent is not available and
resolve ambiguities between homozygous and
hemizygous in the absence of two alleles. Additionally,
characterization of more deletion patients, family linkage
analysis or animal models with targeted mutations of can-
didate genes will be useful approaches to refine this criti-
cal interval and possibly identify the gene involved.
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